logo-loader

BioVie presents rationale for NE3107 trial in Parkinson's Disease treatment at IAPRD in Chicago

Published: 16:39 16 May 2023 EDT

BioVie Inc -

BioVie Inc (NASDAQ:BIVI) has announced that a poster detailing the supporting data and rationale for a potentially pivotal clinical trial of the company's drug candidate NE3107 in the treatment of Parkison’s Disease was presented at the 2023 World Congress on Parkison’s Disease and Related Disorders (IAPRD), which held in Chicago on May 13 to 16, 2023.

The drug therapies developer said highlights from the NE3107 study included patients treated with NE3107 + carbidopa/levodopa (C/L) experiencing greater improvements in their Motor Disease Society- Unified Parkinson's Disease Rating Scale (MDS UPDRS) Part III score than patients treated with placebo + C/L at the 2- and 3-hour marks.

As well, the company stated that patients younger than 70 years old treated with NE3107 + C/L experienced improvements that were about 6 points better than those who received placebo + C/L.

“Throughout the past several months, data reported or presented at major medical conferences have established a compelling rationale for further clinical evaluation of NE3107 in Parkinson’s Disease,” BioVie CEO Cuong Do said in a statement.

“We were pleased to present these summarized findings at the IAPRD, and look forward to advancing our program to explore the unique mechanism of action of NE3107 in a potentially pivotal Phase 3 study.” 

The company said the study met its endpoints, with investigators concluding that NE3107 + C/L combination treatment was associated with clinically meaningful and superior improvements (3+ points) on the motor examination part (Part III) of the MDS UPDRS.

As well, BioVie noted that results from the Alzheimer’s Disease (AD) Phase 2 study showed that NE3107 was associated with improvements in neurophysiological, neuropsychological, and biomarker status, and the treatment was associated with several patient and study partner reported benefits, including improved mood and memory.

The company added that no adverse safety signal has been observed in any clinical study of NE3107.

BioVie is developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.

Contact Sean at sean@proactiveinvestors.com

Breaking News: CEO Reveals Stunning Results in Alzheimer's & Parkinson's...

  BioVie Inc (NASDAQ:BIVI) CEO Cuong Do joined Steve Darling from Proactive to share news the company will be presenting its blinded data on cognitive, biomarker, and imaging findings from the recently completed Phase 3 clinical trial of NE3107 in the treatment of mild to moderate Alzheimer’s...

on 10/25/2023